Related Tags

Tags: spms + treatment.with.MS

Sort by: Date / Title / URL

  1. BioMS Medical initiates follow-on open-label MAESTRO-02 Multiple Sclerosis trial of MBP8298
    BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), today announced that it has initiated MAESTRO-02, the open-label follow-on portion to its MAESTRO-01 pivotal phase II/III clinical trial of MBP8298
    05-03-2007 to , , , , , by admin
  2. Cambridge Antibody - ABT-874
    ABT-874 is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases.
    30-07-2006 to , , , , , , , , by admin
  3. Campath-1H - multiple sclerosis encyclopaedia
    In one small trial of 27 people with Secondary Progressive MS (SPMS), the drug was found to virtually eliminate the formation of new lesions and the inflammation associated with the disease for at least eighteen months.
    22-07-2006 to , , , , , by admin
  4. National MS Society | Novantrone (Mitoxantrone)
    Novantrone belongs to the general group of medicines called antineoplastics. Prior to its approval for use in MS, it was used only to treat certain forms of cancer. It acts in MS by suppressing the activity of T cells, B cells, and macrophages that are th
    21-07-2006 to , , , , , , by admin
  5. BioMS Medical expands pivotal multiple sclerosis trial into The Netherlands
    BioMS Medical Corp (TSX: MS), a leadingdeveloper in the treatment of multiple sclerosis (MS), today announced it hasreceived approval to start patient enrolment in The Netherlands for itspivotal phase II/III clinical trial of MBP8298, a proprietary synthe
    22-06-2006 to , , , , , by admin

First / Previous / Next / Last / Page 1 of 1